The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Immunocore
Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.
 
Takami Sato
Research Funding - Guerbet (Inst); Lilly (Inst)
 
Paul D. Nathan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Leonel Fernando Hernandez-Aya
No Relationships to Disclose
 
Joseph J Sacco
No Relationships to Disclose
 
Marlana M. Orloff
No Relationships to Disclose
 
Jessica Truscello
No Relationships to Disclose
 
Cheryl McAlpine
Employment - Immunocore
 
Ann-Marie Hulstine
Employment - Immunocore
 
Mark C. Lanasa
Employment - Immunocore; MedImmune
 
Christina Marie Coughlin
Employment - Immunocore
Leadership - Immunocore
 
Richard D. Carvajal
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb; Castle Biosciences; Genentech/Roche; Iconic Therapeutics; Janssen Oncology; Merck; Novartis